StockNews.AI
FOLD
StockNews.AI
120 days

Amicus Therapeutics to Announce First Quarter 2025 Financial Results on May 1, 2025

1. Amicus Therapeutics will host Q1 financial results call on May 1, 2025. 2. Registration is required for participants to access the call. 3. Archived materials will be available post-event on the company’s website. 4. Amicus focuses on high-quality medicines for rare diseases.

Earnings
+0.07%Current Return
VS
-0.72%S&P 500
$6.8304/21 07:05 AM EDTEvent Start
$6.83504/22 01:34 PM EDTLatest Updated
3m saved
Insight
Article

FAQ

Why Bullish?

The impending earnings call often leads to market interest. Positive results could enhance investor confidence, contributing to potential price increase.

How important is it?

The earnings call allows investors to assess Amicus's performance; relevant for stock valuation. Positive disclosures may boost FOLD’s prices.

Why Short Term?

Upcoming earnings call set for May 1 may swiftly influence stock prices. Historical precedent shows stock volatility pre-earnings announcements.

Related Companies

EDITNTRARAVN
April 21, 2025 07:00 ET  | Source: Amicus Therapeutics, Inc. PRINCETON, N.J., April 21, 2025 (GLOBE NEWSWIRE) -- Amicus Therapeutics (Nasdaq: FOLD) today announced that the Company will host a conference call and live audio webcast on Thursday, May 1, 2025, at 8:30 a.m. ET to discuss financial results for the first quarter ended March 31, 2025. Participants and investors interested in accessing the call by phone will need to register using the online registration form. After registering, all phone participants will receive a dial-in number along with a personal PIN to access the event. A live audio webcast and related presentation materials can also be accessed via the Investors section of the Amicus Therapeutics corporate website at ir.amicusrx.com. Web participants are encouraged to register on the website 15 minutes prior to the start of the call. An archived webcast and accompanying slides will be available on the Company's website shortly after the conclusion of the live event. About Amicus Therapeutics Amicus Therapeutics (Nasdaq: FOLD) is a global, patient-dedicated biotechnology company focused on discovering, developing and delivering novel high-quality medicines for people living with rare diseases. With extraordinary patient focus, Amicus Therapeutics is committed to advancing and expanding a pipeline of cutting-edge, first- or best-in-class medicines for rare diseases. For more information please visit the company’s website at www.amicusrx.com, and follow on X and LinkedIn. CONTACT: Investors:Amicus TherapeuticsAndrew FaughnanVice President, Investor Relationsafaughnan@amicusrx.com (609) 662-3809 Media:Amicus TherapeuticsDiana MooreHead of Global Corporate Affairs and Communications dmoore@amicusrx.com (609) 662-5079 FOLD–G

Related News